John Hanna - Veracyte Chief Commercial Officer
| VCYT Stock | USD 19.31 0.17 0.87% |
Executive
Mr. John W. Hanna is Chief Commercial Officer of the Company. As chief commercial officer, Mr. Hanna will oversee sales, marketing and managed care for Veracyte, continuing to report to Mr. Hall. Mr. Hanna joined Veracyte in 2011, most recently serving as vice president of marketing. During his tenure, he has helped define clear patientcentric value propositions for Veracyte genomic tests, leading to broad physician adoption and health plan reimbursement. Prior to Veracyte, Mr. Hanna held management positions in business strategy and development at IBM and Humana. since 2017.
| Tenure | 7 years |
| Address | 6000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 243 6300 |
| Web | https://www.veracyte.com |
Veracyte Management Efficiency
Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.01 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 19.6 M in 2024. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Fang Zhang | Structure Therapeutics American | N/A | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Beth Mueller | AnaptysBio | N/A | |
| Robert Goodenow | Syndax Pharmaceuticals | 62 | |
| Stephen MBA | Solid Biosciences LLC | 65 | |
| Jorge Quiroz | Solid Biosciences LLC | 48 | |
| Stuart MD | Cytokinetics | N/A | |
| Lionel Carnot | Merus BV | 49 | |
| Mark Throsby | Merus BV | N/A | |
| Monique Silva | AnaptysBio | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Gregory Perry | Merus BV | 64 | |
| MD JD | Rocket Pharmaceuticals | N/A | |
| Amin Abujoub | Uniqure NV | N/A | |
| Andres CPA | Ideaya Biosciences | 37 | |
| Paul Barsanti | Ideaya Biosciences | N/A | |
| Jennifer Lee | Rhythm Pharmaceuticals | 48 | |
| Aaron Ondrey | Rocket Pharmaceuticals | 47 | |
| Jennifer JD | Viridian Therapeutics | N/A | |
| Christine Sheehy | MeiraGTx Holdings PLC | 56 | |
Management Performance
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0099 |
Veracyte Leadership Team
Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelly Guyer, CFO, Principal Accounting Officer and Member of Non-Management Equity Award Committee | ||
| Brian Atwood, Chairman of the Board | ||
| Neil Barth, Chief Medical Officer | ||
| Christopher Hall, COO | ||
| Mark Ho, Principal Accounting Officer | ||
| Robert Epstein, Director | ||
| Kevin Gordon, Director | ||
| Karin Eastham, Director | ||
| Evan Jones, Director | ||
| Keith Kennedy, CFO | ||
| Corinne Danan, Senior President | ||
| Tina Nova, Director | ||
| Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee | ||
| John Bishop, Director | ||
| Angie McCabe, IR Contact Officer | ||
| Rebecca Chambers, Executive CFO | ||
| Jonathan Wygant, VP Officer | ||
| Jackie Cossmon, IR Contact Officer | ||
| Beverly CPA, VP Controller | ||
| Julie Brooks, Executive Vice President General Counsel, Secretary | ||
| Steven French, Senior Officer | ||
| Fred Cohen, Director | ||
| Robert Brainin, Executive Officer | ||
| John Leite, Chief Business | ||
| Annie McGuire, Sr Counsel | ||
| Tracy Morris, VP Communications | ||
| Jesse Treu, Director | ||
| Phillip MD, Chief Officer | ||
| John Hanna, Chief Commercial Officer | ||
| Karen Possemato, Communications Marketing | ||
| Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer | ||
| Marc Stapley, CEO Director |
Veracyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0099 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 75.07 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 97.08 % | ||||
| Number Of Shares Shorted | 3.64 M | ||||
| Price To Earning | (10.61) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Veracyte Stock analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 4.97 | Quarterly Revenue Growth 0.223 | Return On Assets (0.01) | Return On Equity (0.07) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.